Proposed Rules. Notice
/register/2002/10/23/02-26875·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Agency: Food and Drug Administration, HHS
Action: Notice
Citation: FR Doc. 02-26875 · Docket No. 02N-0012
Summary
The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Postmarketing Adverse Drug Experience Reporting” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).
Supplementary Information
In the Federal Register of July 22, 2002 (67 FR 47821), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0230. The approval expires on September 30, 2005. A copy of the supporting statement for this information collection is available on the Internet at . Dated: October 16, 2002. Margaret M. Dotzel, Associate Commissioner for Policy. [FR Doc. 02-26875 Filed 10-22-02; 8:45 am]